Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program
ZUG, SWITZERLAND AND VILNIUS, LITHUANIA / ACCESS Newswire / March 4, 2025 / Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB, which is the first-in-class dual-active domain targeted medicine that will enter the clinic in the coming months as an investigational therapeutic to treat Atopic Dermatitis.
Micreos is focused on developing best-in-class targeted therapeutics to precisely target harmful pathogens that cause disease flares to help address significant unmet medical needs in dermatology and oncology.
As part of the partnership, Northway Biotech will apply its significant expertise in biologics manufacturing to develop a scalable GMP production process for Micreos' engineered endolysin technology. The collaboration will also include developing and validating robust analytical methods, cell bank manufacturing, technology scale-up for cGMP Drug Substance generation, and IND/IMPD supporting documentation preparation, to ensure that the production of Micreos' engineered endolysins complies with stringent regulatory standards for clinical trials.
Matt Regan, CEO of Micreos, stated: "This partnership with Northway Biotech marks a significant milestone for Micreos as we advance our engineered endolysins into scalable therapeutics for clinical trials. By developing targeted medicines that address the underlying pathophysiology associated with disease aggravation in conditions such as atopic dermatitis and cutaneous T-Cell lymphoma, and by leveraging Northway's significant manufacturing expertise, we are poised to make a meaningful impact on patient care in areas of great unmet medical need."
Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech, highlighted the mutual commitment to high-quality manufacturing: "We are honored to contribute to Micreos' innovative engineered endolysin therapies. With a dedicated and highly experienced team in recombinant protein process development and scale-up, we aim to accelerate Micreos' development by providing cGMP drug substance material available by the end of summer 2024."
André Markmann, PhD, VP of Business Development at Northway Biotech, added: "Micreos' engineered endolysins address critical healthcare challenges. We are excited to support Micreos in advancing their breakthrough therapy into clinical trials at a rapid pace while ensuring the highest standards."
About MEndoB
Micreos' MEndoB is the first-in-class and potentially best-in-class dual-active domain, targeted medicine designed for optimum activity on human skin. It works through targeted enzymatic degradation of the targets cell wall, rapidly killing the harmful pathogen, but without triggering drug resistance or having any off target affects. Micreos' engineering expertise has enhanced drug stability and activity but has also been validated to effectively penetrate biofilms, eliminate dormant & hard to kill pathogenic cells, and potentially deliver synergies with other medications. With demonstrated preclinical efficacy, MEndoB holds significant promise for treating chronic and difficult-to-treat conditions in dermatology and oncology.
About Micreos
Micreos is a preclinical-stage biopharmaceutical company developing highly innovative, targeted therapies as a new way to treat chronic conditions in dermatology and oncology where there is a high unmet medical need. With its advanced engineering platform, Micreos is developing targeted medicines that selectively eliminate harmful pathogens while preserving the beneficial microbiome, paving the way for future indications in dermatology, oncology, and beyond.
For more information, visit www.micreos.com.
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise and vertically integrated service offering enables rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA.
For more information, please visit www.northwaybiotech.com.
Micreos Contact:
Matt Regan
CEO and Board member, Micreos Pharmaceutical AG
m.regan@micreos.com
Northway Biotech Contact:
Vladas Algirdas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
View the original press release on ACCESS Newswire
Northway Biotech
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Intersects 41.0m Grading 13.2 g/t Pt.eq at the Current Project4.3.2025 08:12:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / March 4, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) is pleased to announce the latest results from its ongoing winter drilling program at its 100%-owned Thunder Bay North Critical Minerals Project ("TBN"). The second set of assay results has confirmed that the near-surface, high-grade mineralization at the Current deposit is more extensive and significant than previously anticipated. Notably, one hole intersected 41.0 meters grading 13.2 g/t Pt.eq including 10.0 meters with 1.57% Cu and 22.39 g/t Pt.eq. The newly modeled shape of this high-grade area strongly resembles the "Ballroom" structures associated with the JM Reef in the Stillwater Complex in Montana. The high-grade zone intersected in hole CL25-005 and in several adjacent high-grade areas remains open laterally and at depth, significantly enhancing the exploration potential at the Current deposit.Assay results for the remaining seven h
Historic Global Anti-Scam Summit Convenes in London to Combat Escalating Online Fraud4.3.2025 01:00:00 CET | Press release
The World's largest gathering of international leaders, law enforcement, and industry experts aims to reshape the fight against global scams LONDON, GB / ACCESS Newswire / March 4, 2025 / In a landmark event, the United Kingdom will host the Global Anti-Scam Summit (GASS) London 2025, bringing together an unprecedented number of policymakers, industry leaders, and cybersecurity experts. This summit, organized by the UK Home Office, Global Anti-Scam Alliance (GASA), Cifas, and Euroconsumers, is set to be the most significant anti-scam event to date, with a focus on forging global partnerships to address the rampant rise of online scams, which last year cost the global economy nearly US$1.03 trillion. Unveiling Global Strategies Against Scams The summit will kick off with keynote speeches from top international figures, including The Rt Hon Lord Hanson of Flint, who will outline the UK's initiatives and the collaborative efforts needed to combat this global menace. Discussions will focus
GA-ASI Welcomes USAF Designation for New CCA: YFQ-42A3.3.2025 20:45:00 CET | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 3, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI) welcomes the U.S. Air Force's designation for its Collaborative Combat Aircraft: the new uncrewed jet fighter will be called the YFQ-42A. The announcement on Monday followed an earlier USAF decision in 2024 that GA-ASI was selected to develop and build the YFQ-42A. "We're proud to get a new official aircraft designation," said GA-ASI President David R. Alexander. "YFQ-42A continues a long and distinguished history for GA-ASI that dates back to the 1990s and the debut of the RQ-1 Predator®, which later changed to MQ-1 Predator. That uncrewed aircraft gave way to the MQ-9A Reaper®, the MQ-20 Avenger®, our new MQ-9B SkyGuardian® and SeaGuardian®, and many others. "These aircraft represent an unrivaled history of capable, dependable uncrewed platforms that meet the needs of America's warfighters and point the way to a significant new era for airpower." The Air Force selected YFQ-42
Polaris Renewable Energy Announces Closing Of Acquisition In Puerto Rico3.3.2025 17:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / March 3, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company"), is pleased to announce that it has closed on the Equity Capital Contribution Agreement ("ECCA") and LLC Agreement with respect to Punta Lima Wind Farm LLC (a wholly owned subsidiary of Santander Bank N.A. -"Santander"-). The project is an operating onshore wind farm called Punta Lima Wind Farm ("PLWF" or the "Project") with a nameplate capacity of 26.0 MW's located in the Municipality of Naguabo, Puerto Rico. The Project was re-constructed and recommissioned by Santander and has a 20-year power purchase agreement ("PPA") in place with Puerto Rico Electric Power Authority (PREPA) terminating in March 2044. The transaction has been completed using a tax-equity structure which results in Polaris becoming the manager and operator of the Project with a controlling equity interest and Santander retaining a tax equity interest in the Project. The transaction was subject to cus
MBZUAI Unveils First-of-its-Kind Undergraduate Program in Artificial Intelligence Designed to Empower Future AI Leaders3.3.2025 12:30:00 CET | Press release
ABU DHABI, AE / ACCESS Newswire / March 3, 2025 / The Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) is disrupting the AI education landscape with the launch of its first-ever undergraduate program. Unlike traditional AI curricula, this Bachelor of Science in Artificial Intelligence program blends core AI expertise with leadership, entrepreneurship, industry experience, and real-world impact. MBZUAI's undergraduate program is innovative and multidisciplinary as it will equip students with a strong foundation in AI fields such as machine learning, natural language processing, computer vision, and robotics, and provide cross-disciplinary training in business, finance, industrial design, market analysis, management, and communication. Students will benefit from a hands-on experiential curriculum to develop an entrepreneurial mindset to lead AI transformations. The goal is to develop visionary thinkers and multi-faceted problem-solvers who will lead the AI evolution globa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom